Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Financing Activities (2016 - 2025)

Coherus Oncology's Cash from Financing Activities history spans 12 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 3398.27% year-over-year to $8.1 million; the TTM value through Dec 2025 reached -$273.7 million, down 46.39%, while the annual FY2025 figure was -$273.7 million, 46.39% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $8.1 million at Coherus Oncology, up from $2000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $54.3 million in Q2 2023 and bottomed at -$281.5 million in Q2 2025.
  • The 5-year median for Cash from Financing Activities is $994000.0 (2021), against an average of -$14.2 million.
  • The largest annual shift saw Cash from Financing Activities soared 7434.67% in 2023 before it tumbled 445.93% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $1.5 million in 2021, then skyrocketed by 343.38% to $6.6 million in 2022, then tumbled by 94.45% to $366000.0 in 2023, then tumbled by 36.89% to $231000.0 in 2024, then skyrocketed by 3398.27% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Cash from Financing Activities are $8.1 million (Q4 2025), $2000.0 (Q3 2025), and -$281.5 million (Q2 2025).